


ABSTRACT

The present invention provides compounds of formula I:



I

wherein G is a small group selected from hydrogen or C₁₋₃ alkyl, Q is pyridine or pyrimidine, and R¹ - R³ are as defined in the specification. These compounds are selective JNK inhibitors showing good activity against the three isoforms of JNK (JNK1, JNK2 and JNK3) and relatively low activity against p38 kinase. The compounds are therefore useful for treating JNK-mediated diseases, especially neurodegenerative diseases in which all three JNK isoforms are implicated.

10005133-120501
T05021-EEF50007